Portal vein tumor thrombus (PVTT) and microvascular invasion (MVI) are types of intrahepatic vascular metastasis of hepatocellular carcinoma (HCC) and are highly correlated with poor prognosis. However, the underlying biomarkers of PVTT and MVI are unclear.
We identified a PVTT/MVI-associated gene S100P by cDNA microarray analysis, and assess the potential value of serum S100P measurement in the differential diagnosis of HCC and prediction of MVI status with large retrospective and perspective cohort studies.
The mRNA and protein of S100P was increased in HCCs with PVTT or MVI. High S100P immunostaining in tumors was correlated with inferior tumor-free survival. Serum S100P values discriminated patients with HCCs from those with benign liver tumors, and it showed predictive potential of MVI status in both retrospective and perspective cohorts. S100P may regulate HCC tumorigenicity and invasive ability; S100P also was associated with up-regulation of CD44, which may mediate HCC cell adhesion to form PVTT/MVI.
Serum S100P may be a novel differential diagnostic marker for HCC and a potential predictor of MVI status pre-surgery for HCC patients. S100P overexpression in HCC is highly correlated with the formation of PVTT and MVI, which may make S100P as a potential therapeutic target for HCC metastasis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–55. https://doi.org/10.1093/annonc/mdy308.
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53. https://doi.org/10.1053/j.gastro.2015.12.041.
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N, Liver Cancer Study Group of J (2016) Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65(5):938–943. https://doi.org/10.1016/j.jhep.2016.05.044
Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62(4):848–54. https://doi.org/10.1016/j.jhep.2014.11.005.
Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Xiao HS, Qin LX, Han ZG. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44(10):1117–21. https://doi.org/10.1038/ng.2391.
Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111. https://doi.org/10.1016/j.ccr.2006.06.016.
Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–9. https://doi.org/10.1016/j.cell.2004.07.011.
Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207(2):541–7. https://doi.org/10.1111/j.1432-1033.1992.tb17080.x.
Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the “fused genes” family. Exp Dermatol. 2012;21(9):643–9. https://doi.org/10.1111/j.1600-0625.2012.01472.x.
Arumugam T, Ramachandran V, Gomez SB, Schmidt AM, Logsdon CD. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012;18(16):4356–64. https://doi.org/10.1158/1078-0432.CCR-12-0221.
Austermann J, Nazmi AR, Muller-Tidow C, Gerke V. Characterization of the Ca2+ -regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem. 2008;283(43):29331–40. https://doi.org/10.1074/jbc.M806145200.
Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15(2):96–109. https://doi.org/10.1038/nrc3893.
Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Ryu JC, Park WS, Lee JY, Nam SW. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol. 2009;35(6):1257–64.
Yuan RH, Chang KT, Chen YL, Hsu HC, Lee PH, Lai PL, Jeng YM. S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS ONE. 2013;8(6):e65501. https://doi.org/10.1371/journal.pone.0065501.
Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu G, Chen Z, Xu Y, Liu L, Luo D, Cao Z, Shi G, Feng Z, Deng H, Liao Q, Cai C, Liao DF, Wang J, Jin J, Cao D. A large-scale multicenter study validates Aldo-Keto reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma. Hepatology. 2019;69(6):2489–501. https://doi.org/10.1002/hep.30519.
Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127(6):603–8. https://doi.org/10.1067/msy.2000.105498.
Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL, Tan SB. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254(1):108–13. https://doi.org/10.1097/SLA.0b013e31821ad884.
Shen Z, Deng H, Fang Y, Zhu X, Ye GT, Yan L, Liu H, Li G. Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma. Oncotarget. 2015;6(24):20672–84. https://doi.org/10.18632/oncotarget.3967.
Shen ZY, Fang Y, Zhen L, Zhu XJ, Chen H, Liu H, Jiang B, Li GX, Deng HJ. Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma. Cancer Genet. 2016;209(4):143–53. https://doi.org/10.1016/j.cancergen.2016.02.002.
Al-Othman N, Alhendi A, Ihbaisha M, Barahmeh M, Alqaraleh M, Al-Momany BZ. Role of CD44 in breast cancer. Breast Dis. 2020;39(1):1–13. https://doi.org/10.3233/BD-190409.
Jiang H, Hu H, Lin F, Lim YP, Hua Y, Tong X, Zhang S. S100P is overexpressed in squamous cell and adenosquamous carcinoma subtypes of endometrial cancer and promotes cancer cell proliferation and invasion. Cancer Invest. 2016;34(10):477–88. https://doi.org/10.1080/07357907.2016.1212206.
Kim J, Jiang J, Badawi M, Schmittgen TD. miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway. Biochem Biophys Res Commun. 2017;487(3):709–15. https://doi.org/10.1016/j.bbrc.2017.04.121.
Wu Z, Boonmars T, Nagano I, Boonjaraspinyo S, Srinontong P, Ratasuwan P, Narong K, Nielsen PS, Maekawa Y. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma. Int J Cancer. 2016;138(2):396–408. https://doi.org/10.1002/ijc.29721.
Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids. 2011;41(4):893–9. https://doi.org/10.1007/s00726-010-0496-4.
Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006;98(24):1806–18. https://doi.org/10.1093/jnci/djj498.
Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23(8):1531–8. https://doi.org/10.1038/sj.onc.1207269.
This work was supported by the National Nature Science Foundation of China (NSFC 81972306, 81960450, 81860502, 81502533), and Guangxi Nature Sciences Grants (2018GXNSFAA138028, 2018GXNSFAA050124, Gui Ke AB16380242). This work was also supported in part by the Guangxi BaGui Scholars Special Fund and the Guangxi Medical University Training Program for Distinguished Young Scholars.
Conflict of interest
Lu-Nan Qi declares that he has no conflict of interest. Liang Ma declares that he has no conflict of interest. Fei-Xiang Wu declares that he has no conflict of interest. Yuan-Yuan Chen declares that he has no conflict of interest. Wan-Ting Xing declares that he has no conflict of interest. Zhi-Jun Jiang declares that he has no conflict of interest. Jian-Hong Zhong declares that he has no conflict of interest. Zu-Shun Chen declares that he has no conflict of interest. Wen-Feng Gong declares that he has no conflict of interest. Jia-Zhou Ye declares that he has no conflict of interest. Hong-Hao Li declares that he has no conflict of interest. Jin-Jie Shang declares that he has no conflict of interest. Bang-De Xiang declares that he has no conflict of interest. Le-Qun Li declares that he has no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Tumor Hospital of Guangxi Medical University No. LW2018035) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent in studies with human subjects
Informed consent was obtained from all patients for being included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Qi, LN., Ma, L., Wu, FX. et al. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. Hepatol Int 15, 114–126 (2021). https://doi.org/10.1007/s12072-020-10130-1
- Cell migration
- Cell invasion
- Skeleton rearrangement
- Benign liver tumor
- Early stage
- Tumor-free survival